Aetna Step Therapy Denial Appeal 2026: Exception Process, CPBs & Fail-First Override

Why Aetna Step Therapy Denials Require a Split-Track Approach

Aetna step therapy denials are more complex than they appear because Aetna's merger with CVS Health in 2018 split clinical review across two separate systems — and the exception process differs depending on which system issued the denial.

Specialty drug step therapy for most Aetna members routes through CVS Caremark's pharmacy benefit management system, which uses its own drug formulary, step criteria, and prior authorization portal. Medical benefit step therapy — infusions, biologics administered in-office, Part B drugs — stays with Aetna directly and references Aetna's Clinical Policy Bulletins (CPBs) and internal medical necessity criteria.

According to the AMA's 2024 Prior Authorization Physician Survey (n=1,004 physicians), 89% of physicians report prior authorization requirements delay access to necessary care, and step therapy requirements were among the most frequently cited barriers. Specialty practices that prescribe biologics, DMARDs, or high-cost specialty drugs face Aetna step therapy denials regularly — and the practices that win them consistently identify the right track before drafting anything.

The CVS Caremark vs. Aetna Split: Which Track Are You On?

The first step in any Aetna step therapy appeal is determining which entity issued the denial — this defines the exception process, the submission address, and the decision timeline.

The denial letter header and contact information identify the reviewing entity. If the denial came from CVS Caremark (including CVS Specialty or SilverScript for Medicare Part D), the exception request goes to CVS Caremark, not Aetna. If the denial came from Aetna's medical management or utilization review team, the exception request and any formal appeal go through Aetna's standard appeals process.

The 5 Grounds for a Step Therapy Exception

Aetna and CVS Caremark both recognize five exception grounds that allow a patient to bypass the step therapy requirement without completing the required drug trial. Identifying which ground applies is the foundation of a successful exception request — vague appeals citing general medical necessity without specifying an exception ground are routinely upheld.

The five recognized exception grounds are:

1. Contraindication to the Required Step Drug

The required step drug is medically contraindicated for the patient based on a documented allergy, adverse drug interaction, comorbidity, or FDA black box warning applicable to the patient's clinical situation. This is the strongest exception ground because it is binary — if a true contraindication exists, the step requirement cannot be enforced.

Documentation required: documentation of the specific contraindication (allergy record, interaction check, or treating physician attestation referencing the clinical basis).

2. Prior Trial Failure

The patient has previously tried the required step drug — under the current plan or a prior health benefit plan — and discontinued it due to lack of efficacy, diminished effect, or clinically significant adverse effects. Aetna state-specific exception documents confirm this ground explicitly.

Documentation required: dates of trial, prescribed dose, duration of trial, reason for discontinuation, and clinical outcomes during the trial. A trial of inadequate duration or inadequate dose does not qualify — Aetna will apply the step criteria standard to assess whether the prior trial was adequate.

3. Concurrent Medication Conflict

The required step drug is contraindicated by a concurrent medication the patient is currently taking, or the combination creates a clinically significant interaction risk. This differs from a general contraindication in that the conflict is drug-drug rather than drug-patient.

Documentation required: current medication list with prescribing indications; clinical literature or prescribing information (package insert or FDA labeling) documenting the interaction.

4. Inaccessibility or Unavailability

The required step drug is not reasonably available — for example, the specific drug is on back-order, unavailable through the patient's assigned pharmacy network, or requires administration not feasible given the patient's location or medical condition. This ground is narrower and less commonly used, but valid when documented.

Documentation required: documentation from the pharmacy or dispensing facility confirming unavailability, with dates.

5. Clinical Exception Based on Medical Necessity

The required step drug is not in the patient's best interest based on medical necessity — meaning the prescribing physician documents that, given the patient's specific clinical characteristics, the required drug is clinically inappropriate or contraindicated even if not listed in a formal contraindication table.

This is the broadest exception ground and the most commonly contested. It requires a physician attestation letter that ties the clinical argument directly to the Aetna CPB or CVS Caremark clinical guideline cited in the denial. Generic "medically necessary" language does not meet the standard — Aetna requires the attestation to engage the specific criteria the required step drug failed to meet.

How to Request an Aetna Step Therapy Exception

The exception request process follows the same prior authorization workflow — you submit it the same way a new prior authorization is submitted.

For Aetna medical benefit:

1. Submit via NaviNet (preferred) or Availity — log in, locate the prior authorization or step therapy exception request section for the member's plan
2. Alternatively, submit via fax to Aetna at 1-860-975-3275 with a completed prior authorization/step exception request form
3. Include: denial reference number, clinical documentation supporting the applicable exception ground, physician attestation letter, relevant Aetna CPB reference, and supporting literature if using the clinical exception ground

For CVS Caremark pharmacy benefit:

1. Submit via CVS Caremark's online provider portal or call 1-800-294-5979
2. For specialty drugs, use the CVS Specialty PA portal or CoverMyMeds for electronic submission
3. Include: CVS Caremark PA reference number from the denial, drug name and dosage, exception ground documentation, and prescriber attestation

Decision timelines:

• Standard exception decision: 72 hours (3 calendar days)
• Expedited/urgent exception decision: 24 hours — available when the prescribing physician certifies that the standard timeline would seriously jeopardize the patient's life, health, or ability to regain maximum function
• For Medicare Advantage: same timelines apply; expedited requests must have physician documentation of urgent medical need

Step-by-Step: Building the Exception Request Documentation Package

A complete exception request has three components: the exception ground argument, the clinical documentation, and the CPB or formulary policy engagement.

Component 1: Identify and State the Exception Ground

Open the exception request (or physician attestation letter) by identifying the specific exception ground you are asserting and the Aetna CPB or CVS Caremark guideline that governs the denied drug. The denial letter must reference the clinical policy cited. If it does not — and the denial involves a Medicare Advantage member after January 1, 2026 — note the omission as a CMS-0057-F compliance deficiency.

Component 2: Compile Clinical Documentation by Exception Ground

Different exception grounds require different documentation packages:

Component 3: Cite the Relevant Aetna CPB

For medical benefit step therapy, the denial letter references an Aetna Clinical Policy Bulletin (CPB). The CPB defines the clinical criteria the required step drug is supposed to meet — and your exception request needs to explain why the step drug cannot meet those criteria for this patient.

Aetna's public CPB index is available at aetna.com/cpb/medical/data/ — all major CPBs are publicly accessible without login. Find the CPB number from the denial letter, pull the current version, and identify:

1. The specific step therapy language (usually listed under "Medical Necessity" or "Prior Authorization" criteria)
2. The criteria that apply to the requested drug
3. The clinical characteristics your patient presents that support exception

Aetna updates CPBs regularly. If the CPB has been updated since the date of service, check whether the updated version is more favorable and note the update date in your exception request.

How to Appeal After a Step Exception Is Denied

If the step exception request is denied, you have the right to file a formal written appeal. The appeal window runs from the exception denial date — do not restart the clock from the original step denial.

Commercial appeal timeline: 180 calendar days from the denial date. Check your Aetna provider contract, which may specify a shorter window.

Medicare Advantage appeal timeline: 60 calendar days from the denial notice. For MA, the five-level CMS appeal ladder applies:

1. Organization Determination (OD) — the initial PA or step exception decision
2. Reconsideration by an Independent Review Entity (IRE) — 60 days from OD denial
3. Administrative Law Judge (ALJ) hearing — amounts-in-controversy threshold (~$230 in 2026)
4. Medicare Appeals Council (MAC)
5. Federal district court

What changes in a formal appeal vs. the exception request:

The exception request goes to Aetna's or CVS Caremark's utilization management team. The formal appeal goes to a separate appeals reviewer. The formal appeal can also include additional clinical evidence not submitted during the exception request — new literature, specialist letters, updated chart notes. For clinical exception ground appeals, the formal appeal should expand the clinical argument and directly address the specific reason the exception was denied.

For a complete Aetna appeals process overview covering all denial types, see the Aetna denied claim and appeal guide. If the appeal also involves a prior authorization denial (not just step therapy), see the Aetna prior authorization template and appeal guide.

State Step Therapy Laws That Expand Your Exception Rights

For fully-insured commercial Aetna plans, state step therapy laws may create additional exception grounds or mandate faster timelines than Aetna's standard 72-hour process. These laws apply to fully-insured plans regulated by the state insurance department — they do not apply to self-funded employer plans governed by ERISA.

As of May 2026, more than 30 states have enacted some form of step therapy reform legislation, according to steptherapy.com's state legislation tracker. Coverage varies significantly — some states have robust exception grounds with deemed-granted provisions (Texas), while others have narrower protections. Always check the current state DOI resources for the plan's state of domicile.

CMS-0057-F and Aetna Step Therapy: What Changed in 2026

For Aetna Medicare Advantage plans, CMS Interoperability and Prior Authorization Final Rule CMS-0057-F — effective January 1, 2026 — created two important changes for step therapy denials.

Specific clinical criteria required in denial notices. MA plans must now provide patient-specific clinical reasons for prior authorization and step therapy denials, not just a policy code. If an Aetna MA denial references only a CPB number or a generic "step therapy criteria not met" statement without explaining which specific criterion the patient failed and why, that is a procedural deficiency under 42 CFR §422.568(d). Note this deficiency explicitly in your exception request or appeal letter — it is a ground for reversal independent of the clinical argument.

Faster PA decision timelines codified. CMS-0057-F codified the 72-hour standard and 24-hour expedited timelines for MA prior authorization decisions, which apply to step therapy exception requests made through the MA PA process. If Aetna MA misses the decision deadline, escalate to the plan's grievance process and document the missed deadline in the appeal.

For detailed guidance on appealing Aetna Medicare Advantage denials including step therapy, see the Aetna Medicare Advantage denial appeal guide.

Aetna Step Therapy CPB Citation: A Practical Template

For clinical exception ground appeals, the physician attestation letter should follow this structure:

Aetna Clinical Policy Bulletin [CPB Number], effective [date], establishes
step therapy criteria requiring [specific prior therapy language from CPB].

The patient does not qualify for the required prior therapy based on
[specific clinical characteristic — e.g., documented history of X, comorbidity Y,
concurrent medication Z creating interaction risk].

This is documented in [chart note date / clinical finding]. The requested drug,
[drug name], is appropriate for this patient based on [clinical rationale].
[Clinical guideline or peer-reviewed study] (published [year], [society/journal])
supports [drug name] as [first-line/alternative] therapy in patients with
[patient's clinical characteristics].

The applicable exception ground is: [exception ground from Aetna's policy].

This structure works because it quotes the CPB criterion, explains why the patient cannot meet the step requirement, ties the clinical argument to a specific exception ground Aetna recognizes, and supports the argument with sourced literature.

Aetna's CPBs often reference InterQual criteria or MCG Care Guidelines as supplementary sources — if the applicable CPB does this, check those supplementary criteria as well. Addressing Aetna's policy framework more completely than the denial letter does is the fastest path to an exception or appeal reversal.

Frequently Asked Questions

How long do I have to request a step therapy exception from Aetna?

For commercial plans, you have 180 calendar days from the denial date to file a formal written appeal. Step exception requests should be submitted as early as possible — well before that window — because the standard exception decision takes 72 hours and escalating to a formal appeal takes additional time. For Medicare Advantage, the deadline is 60 days from the denial notice. Check the denial letter, which must state the deadline.

What is the difference between a CVS Caremark step therapy denial and an Aetna step therapy denial?

CVS Caremark manages the pharmacy benefit for most Aetna commercial members — oral and self-injectable specialty drugs, Part D medications. Aetna's medical management team handles the medical benefit — infusions, Part B drugs, biologics administered in the physician's office. CVS Caremark denials use CVS Caremark's formulary and step criteria; Aetna medical benefit denials use Aetna's CPBs. The exception request submission address and process differ between the two, so identifying the reviewing entity from the denial letter header is the critical first step.

Can a patient already stable on a non-step drug be forced to switch?

In Oregon (ORS 743B.602), a patient who is stable on a currently prescribed drug cannot be required to switch to a step drug under a new plan year or formulary change — the "stable patient" exception is explicit in state law. Several other states have similar protections. For ERISA self-funded plans, this protection depends on the plan document. For clinical appeals outside these state protections, argue that forcing a stable patient to trial an alternative drug creates a risk of disease flare, re-stabilization burden, and potential clinical harm — and cite relevant literature on the risk of therapy interruption for the patient's condition.

How do I get an expedited 24-hour step exception decision from Aetna?

The ordering physician must certify in writing that the standard 72-hour decision timeline would seriously jeopardize the patient's life, health, or ability to regain maximum function. Submit the expedited exception request through the same channel (NaviNet or Availity for medical benefit; CVS Caremark portal for pharmacy benefit), and mark it as expedited with the physician certification attached. For Medicare Advantage, Aetna is required under CMS-0057-F to meet the 24-hour expedited PA decision timeline.

Does Aetna's step therapy apply to biosimilars?

Yes, Aetna's step therapy criteria can apply to biosimilars — particularly for infusions and Part B biologics where a biosimilar is designated as the required prior therapy before a reference biologic. If the step therapy requires a biosimilar trial and the prescribing physician has a clinical reason to prescribe the reference biologic directly (e.g., prior biosimilar failure, documented patient intolerance, or FDA indication differences between the biosimilar and the reference product), the clinical exception ground applies. Cite the FDA biosimilar label and any relevant prescribing information differences in the exception request.

What Aetna CPBs cover step therapy for specialty drugs?

Aetna publishes CPBs for most specialty drug categories. The CPB number appears in the denial letter. You can access the public CPB index at aetna.com/cpb/medical/data/. Commonly affected categories include rheumatologic conditions (anti-TNF biologics, JAK inhibitors), dermatology (biologics for psoriasis, atopic dermatitis), gastroenterology (biologics for IBD), neurology (MS disease-modifying therapies), and oncology-adjacent specialty drugs. Each CPB defines the specific step criteria — review the current CPB version before drafting the exception request, as Aetna updates policies regularly.

What happens if Aetna denies both the step exception and the formal appeal?

For fully-insured commercial plans, the next step is state external review through an Independent Review Organization (IRO). The final internal denial letter must include information on how to request external review. IRO review is available for medical necessity and clinical coverage disputes in most states and is binding on the health plan. For a guide to the external review process, see the prior authorization denial complete guide. For Medicare Advantage, escalate through the CMS five-level appeal ladder — the Level 3 ALJ process has historically overturned MA denials at rates above 50% according to OMHA annual report data (fiscal year 2024).

Does CMS-0057-F apply to Aetna commercial step therapy denials?

No. CMS-0057-F applies to Medicare Advantage, Medicaid managed care, CHIP, and ACA Marketplace plans — not commercial employer-sponsored plans regulated under ERISA. For commercial plans, the ERISA claims procedure regulation (29 CFR §2560.503-1), Aetna's provider contract, and applicable state insurance laws govern denial notice requirements and appeal timelines.

Ready to Reverse Aetna Step Therapy Denials Systematically?

Aetna step therapy denials are winnable when the exception request identifies the correct reviewing entity, cites the specific exception ground and CPB criterion, and reaches the correct submission address before the deadline. Most practices lose these denials before the clinical argument is ever reviewed — because the exception request goes to the wrong track, misses the expedited window, or doesn't engage the specific CPB criterion Aetna cited.

Muni Appeals helps billing teams identify whether the denial is from CVS Caremark or Aetna's medical management team, pull the applicable CPB, compile the exception documentation package, and track deadlines across commercial, Medicare Advantage, and state-specific external review windows.

Start 3 Free Appeals:

• Automatic CVS Caremark vs. Aetna medical benefit routing detection
• CPB identification and step criteria matching per denial
• Exception ground documentation checklist by denial type
• Deadline tracking across commercial, MA, and state external review windows

Start 3 Free Appeals

---

This guide reflects Aetna step therapy exception and appeal procedures as of May 2026. State step therapy laws apply only to fully-insured plans — ERISA self-funded plans are governed by plan documents and Aetna provider contracts. CMS-0057-F requirements apply to Medicare Advantage, Medicaid, and ACA Marketplace plans. Muni Appeals maintains current procedures for major insurance companies and insurer-specific appeal workflows.